SOME MARKERS OF HBeAg, ANTI-HBe, HBcrAg, HBV-DNA IN UNTREATED CHRONIC HEPATITIS B PATIENTS AND RELATED FACTORS
Main Article Content
Abstract
Background: Several serological markers have been evaluated for their association with disease severity and have significance in the diagnosis and monitoring of treatment in patients with chronic hepatitis B. Objective: To investigate certain serological markers HBeAg, anti-HBe, HBcrAg levels, HBV-DNA and related factors in untreated patients with chronic hepatitis B at S.I.S Can Tho International General Hospital from 2023 to 2025. Materials and Methods: This is a cross-sectional descriptive study with analytical components conducted on 100 patients with confirmed diagnoses of untreated chronic hepatitis B who visited the Gastroenterology Clinic at S.I.S Can Tho International General Hospital from July 2024 to February 2025. The patients underwent qualitative testing for HBeAg and anti-HBe, quantitative measurement of HBcrAg, and assessment of HBV-DNA viral load. Data were collected and analyzed using SPSS version 25.0. Results: The proportion of patients who HBeAg(+) was 26,0%, anti-HBe(+) was 74,0%, HBcrAg(+) was 80,0%, and HBV-DNA(+) was 97,0%. The mean age of the study population was 48,44±13,1 years, Males were slightly more predominant (51,0%) compared to females (49,0%), and the majority of participants resided in rural areas (76,0%). Among patients with HBeAg(+), the mean ALT activity was 83,5±115,7 U/L, AST was 62,9±63,5 U/L, and the mean concentrations of HBcrAg and HBV-DNA were 7,45±1,45 logU/mL and 5,89±2,47 log₁₀ IU/mL. Conclusion: The proportion of chronic hepatitis B patients with HBeAg(+) was 26,0%, while those with HBeAg(-) made up 74,0%. Patients in the HBeAg(+) group were younger than those in the HBeAg(-) group, with an OR=3,37 (p=0,01). No statistically significant association were found in HBeAg status regarding gender, residence, AST and ALT levels. The mean concentrations of HBcrAg and HBV-DNA were significantly higher in the HBeAg(+) group than in the HBeAg(-) group (p<0,001).
Article Details
Keywords
Chronic hepatitis B, HBV-DNA, HBcrAg, HBeAg
References

2. Lê Đình Vĩnh Phúc (2020), “Nghiên cứu một số đặc điểm kháng nguyên liên quan đến lõi vi rút viêm gan B tại trung tâm MEDIC thành phố Hồ Chí Minh”, Tạp chí Truyền nhiễm Việt Nam, 4(32), tr.80-85.

3. Nguyễn Thị Cẩm Hồng, Đỗ Hoàng Long, Lê Thị Hoàng Mỹ, Trịnh Thị Hồng Của & Phan Hoàng Đạt (2022), “Nghiên cứu các dấu ấn huyết thanh nhiễm HBV, mối tương quan giữa nồng độ HBsAg và tải lượng vi rút ở bệnh nhân viêm gan B mạn chưa điều trị tại Bệnh viện trường Đại học Y Dược Cần Thơ năm 2021-2022, Tạp chí Y Dược học Cần Thơ, 51, 205-212.

4. Lê Văn Nam (2021), “Nghiên cứu mối tương quan giữa tải lượng HBV DNA và hoạt độ enzym ALT ở bệnh nhân viêm gan vi rút B mạn tính”, Tạp chí Y học Việt Nam, 2(500), tr.95-99.

5. Liu D, Xu T, Shi B, Lu W, et al (2020). “Clinical relevance of the in situ assay for HBV DNA: a cross-sectional study in patients with chronic hepatitis B”, J Clin Pathol, 73(12, pp.813-818.

6. Yang N. Feng T, Zhou T, Li Z, et al (2018), “Relationship betwween serum quantitative HBsAg and HBV DNA levels in chronic hepatitis B patients”, J Med Virol, 90(7), pp.1240-1245.

7. Mai Thị Bích Chi (2022), “Khảo sát nồng độ HBcrAg huyết thanh ở bệnh nhân viêm gan B mạn tại bệnh viện đại học y dược TPHCM”, Trường Đại học Y Dược TP.HCM, tr.350-381.
